

December 15, 2023

Michael Davidson
Chief Executive Officer
NewAmsterdam Pharma Co N.V.
Gooimeer 2-35
1411 DC Naarden
The Netherlands

Co N.V.
Statement on Form F-3
2023

Re: NewAmsterdam Pharma
Registration
Filed December 7,
File No. 333-275932

Dear Michael Davidson:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Drory at 202-551-8342 with any questions.

Please contact Jason

Sincerely,

Division of Corporation Finance

Office of Life Sciences

cc:

Brianna M. Bloodgood